📈 Jumpstart Signal Watchlist — November 03, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $15.13 is 3% below 3yr high $15.62 · ⏳ SMA200 $8.39 (current price $15.13 is above) · 💰 Market Cap $854M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.6%)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×1).
✅ Looking for Relative Strength? This Little-Known Stock Checks the Boxes — TheStreet.
🤖 The article highlights Paysign’s recent earnings beating expectations and management raising its full-year revenue outlook, both supportive of the stock. The results and guidance discussed are from the prior quarter, not new results published in this period.
✅ Paysign (NASDAQ:PAYS) Reaches New 52-Week High — MarketBeat.
🤖 Paysign shares reached a new 52-week high, and the article notes a positive analyst rating mix. It also references earlier earnings results and an October 8 rating upgrade.
⚪️ Paysign CEO Mark Newcomer sells $766,895 of PAYS stock — Investing.com.
🤖 The CEO sold 50,000 shares under a previously adopted Rule 10b5-1 trading plan. This is an insider transaction disclosure rather than a reported change in the company’s outlook or operations.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: ACCO Brands designs, manufactures, and markets branded office, school, and consumer products. Its offerings include notebooks and planners, filing and organization supplies, office equipment, computer accessories, and gaming products.
- 🎯 Current $5.19 is 21% below 3yr high $6.59 · ⏳ SMA200 $3.97 (current price $5.19 is above) · 💰 Market Cap $479M
- ACCO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Base breakout (range: 8.8%); Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (10.8%)
- 🔔 Strong above EMA50 (15.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Noble Financial Raises Earnings Estimates for Acco Brands — MarketBeat.
🤖 Noble Financial raised its full-year earnings estimate for ACCO, and the article also notes the company beat consensus EPS estimates in its latest quarter. The estimate increase is a modest positive signal, though the broader analyst consensus remains Hold.
✅ ACCO Brands Reports Third Quarter Results — Yahoo Finance / Business Wire.
🤖 ACCO reported adjusted EPS of $0.28, above the prior-year $0.21, and increased adjusted operating income. It also raised its full-year outlook to 4%–6% reported sales growth and $0.98–$1.02 adjusted EPS, although quarterly sales declined slightly and missed expectations.
⚪️ ACCO Brands Corporation Q3 2026 Earnings Call Summary — Yahoo Finance.
🤖 The summary highlights improved margins, cost savings, and the Trust acquisition, but also reports nearly 6% comparable-sales declines and significant Technology Peripherals headwinds. Tariff refunds materially supported quarterly earnings, making the underlying performance mixed.
🍭 Bonus (B): 0/10 — Printing & Publishing

🏢 What they do: Cytek Biosciences develops cell-analysis systems, especially spectral flow cytometers and cell sorters used by researchers to study cells. It also provides related reagents, software, and services.
- 🎯 Current $5.96 is 37% below 3yr high $9.51 · ⏳ SMA200 $4.69 (current price $5.96 is above) · 💰 Market Cap $779M
- CTKB shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 428% (>20%); Revenue growth 24% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.70 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.5%)
📢 Sentiment (S): 4/10
- 🗞️ News sentiment is negative (❌×1 ⚪️×4; showing 3 of 5).
❌ Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for — Yahoo Finance.
🤖 Analysts expected a year-over-year earnings decline for the upcoming quarter, despite modestly higher revenue. The article also notes that Cytek had missed consensus EPS estimates in each of its prior four quarters.
⚪️ Cytek Biosciences to Participate in Upcoming Investor Conferences — GlobeNewswire.
🤖 Cytek announced its participation in upcoming investor conferences. The announcement provides no new financial results, guidance, or other specific catalyst for the stock.
⚪️ Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability — Yahoo Finance.
🤖 The article describes mixed analyst views: Stephens raised its price target and maintained an Overweight rating, while Morgan Stanley lowered its target and maintained Equal Weight. The modestly higher fair-value estimate is offset by the differing outlooks and profitability concerns.
🍭 Bonus (B): 0/10 — Laboratory Analytical Instruments

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.22 is 11% below 3yr high $12.66 · ⏳ SMA200 $9.50 (current price $11.22 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Vir Biotechnology stock hits 52-week high at $12.02 — Investing.com.
🤖 The article reports that Vir shares reached a 52-week high and cites improved second-quarter results and a raised price target as context. The reported share-price milestone and analyst optimism are positive, though the article was updated after the requested as-of date.
✅ Vir Biotechnology (NASDAQ:VIR) Reaches New 52-Week High — MarketBeat.
🤖 The article reports Vir reached a new 52-week high and notes that its latest reported quarter beat earnings and revenue estimates. These developments are favorable, though the article was updated after the requested as-of date.
⚪️ Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors — Yahoo Finance.
🤖 Vir appointed Suzanne Topalian, a physician and cancer researcher, to its board. The announcement adds relevant expertise but does not describe a direct financial or clinical catalyst.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $79.58 is 3% below 3yr high $82.40 · ⏳ SMA200 $57.36 (current price $79.58 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ red violet Climbs 25 Spots to No. 82 on TIME's America's Growth Leaders of 2027 List — GlobeNewswire.
🤖 Red Violet rose to No. 82 on TIME’s growth-leaders list, up from No. 107, reflecting recognition of its growth and financial performance.
✅ Red Violet (NASDAQ:RDVT) Sets New 1-Year High — MarketBeat.
🤖 The article reports that RDVT reached a new 52-week high and notes that the company’s latest reported quarterly EPS exceeded analyst expectations. It also cites a generally favorable analyst consensus.
❌ Red Violet (NASDAQ:RDVT) Stock Rating Lowered by Zacks Research — MarketBeat.
🤖 Zacks Research downgraded Red Violet from strong buy to hold, a negative analyst-rating change, although the article notes the broader consensus remains favorable.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Porch Group provides homeowners insurance and software for home-related businesses such as inspectors, mortgage providers, and title companies. It also offers consumer services including moving assistance, home warranties, and help arranging home setup and maintenance services.
- 🎯 At/above 3yr high $21.52 (current $21.52) · ⏳ SMA200 $12.16 (current price $21.52 is above) · 💰 Market Cap $2.7B
- PRCH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 46/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); Revenue growth 22% (>15%); ROE 127% (>15%); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (16.7%)
- 🔔 Strong above EMA50 (24.0%)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Porch Group (NASDAQ:PRCH) Stock Rating Raised to Buy at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen upgraded Porch Group from Hold to Buy, and the article also notes higher price targets from several analysts. The rating changes indicate a more favorable analyst outlook.
✅ Porch Group Stock Earnings Beat Raises Guidance After Insurance Growth — Yahoo Finance.
🤖 Porch reported strong third-quarter results, including insurance growth, and raised its full-year guidance. The article also describes a pending acquisition that could expand the company’s insurance business.
⚪️ Porch Group Announces Attendance at Upcoming Investor Events — Business Wire.
🤖 The company announced plans to attend investor conferences and meetings. This is routine investor-relations news and does not report a material business or financial catalyst.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: LTC Properties, Inc. is a real estate investment trust (REIT) focused on senior housing and healthcare properties in the United States. It invests in and leases properties such as skilled nursing facilities, assisted living communities, and memory care facilities to healthcare operators.
- 🎯 At/above 3yr high $45.80 (current $45.80) · ⏳ SMA200 $39.58 (current price $45.80 is above) · 💰 Market Cap $2.5B
- LTC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Base breakout (range: 6.0%); Low drawdown (11.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 75% (>20%); Revenue growth 64% (>15%).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (5.1%)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ LTC Reports 2026 Third Quarter Results as SHOP Momentum Continues — Business Wire.
🤖 LTC reported nearly $950 million in year-to-date SHOP acquisitions, surpassing its previously disclosed midpoint target, and raised its 2026 SHOP investment midpoint to $1 billion. The expansion may support future growth, though the article also notes the company’s updated investment plans rather than a clear earnings outlook improvement.
✅ LTC Approaches 2026 SHOP Acquisition Target of $900 Million with Recent $52 Million Investment — Yahoo Finance.
🤖 LTC announced a $52 million acquisition of a 130-unit senior housing community with low- to mid-90% occupancy, adding to its SHOP portfolio. The deal advances its acquisition growth strategy and includes land with potential for further development.
❌ LTC reports strong Q3 earnings on SHOP acquisitions; 2026 guidance fails to impress — Seeking Alpha.
🤖 LTC beat third-quarter FFO and revenue expectations and raised its SHOP investment midpoint, but its 2026 core FFO guidance midpoint was below consensus. Shares fell in post-market trading, suggesting the guidance shortfall outweighed the earnings beat.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: IDT Corporation provides communications and payment services, including international money transfers, prepaid calling and digital payment products, and wholesale voice and messaging. It also offers point-of-sale and payment-processing tools for independent retailers and cloud-based communications services for businesses.
- 🎯 Current $81.17 is 4% below 3yr high $84.46 · ⏳ SMA200 $59.68 (current price $81.17 is above) · 💰 Market Cap $2.0B
- IDT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (6.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 28% (>20%); ROE 23% (>15%); Low LT D/E 0.02 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ IDT Corporation stock hits all-time high at 83.58 USD — Investing.com.
🤖 The article reports IDT shares reached an all-time high and cites strong fiscal 2026 results, including 7% year-over-year revenue growth and record profitability measures. It also notes Freedom Broker raised its price target to $85 and maintained a Buy rating.
✅ IDT (NYSE:IDT) Sets New 1-Year High - Here's What Happened — MarketBeat.
🤖 The article notes IDT reached a new one-year high and reports Weiss Ratings upgraded the stock to Buy on October 6. It also mentions the prior quarter’s EPS miss, partly offset by revenue above consensus.
⚪️ IDT CFO Marcelo Fischer sells $760,847 in class B common stock — Investing.com.
🤖 The article reports the CFO’s October 15–16 share sales, a backward-looking insider transaction rather than a company operating catalyst. It also mentions strong fiscal 2026 results and a higher analyst price target, but those details are presented as background.
⚪️ IDT director Judah Schorr sells $1.12m in class B common stock — Investing.com.
🤖 The article reports a director’s mid-October stock sales, which are backward-looking transactions and not by themselves a directional catalyst. The article also references strong fiscal 2026 results and an analyst price-target increase as background.
🍭 Bonus (B): 0/10 — Telephone Communications

🏢 What they do: AtriCure develops and sells surgical medical devices and therapies for treating atrial fibrillation, including cardiac ablation systems and devices to manage the left atrial appendage. It also makes cryoablation probes used to help manage pain after surgery.
- 🎯 Current $60.41 is 3% below 3yr high $62.48 · ⏳ SMA200 $38.46 (current price $60.41 is above) · 💰 Market Cap $3.1B
- ATRC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (13.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 238% (>20%); Low LT D/E 0.12 (<1.0); PEG ratio 1.21 (<1.5).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA50 (10.0%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ AtriCure Reports Third Quarter 2026 Financial Results — Yahoo Finance (Business Wire).
🤖 AtriCure reported third-quarter revenue of $154.5 million, up 15% year over year, and raised its full-year 2026 revenue and adjusted EBITDA outlook. The results and higher guidance are positive catalysts.
✅ What AtriCure (ATRC) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 The article highlights 15% revenue growth, a return to quarterly net income, and a 50.6% increase in adjusted EBITDA. It also reports raised full-year revenue guidance, supporting a positive assessment.
⚪️ AtriCure to Participate at Upcoming Investor Conferences — Business Wire.
🤖 The article announces management's participation in upcoming investor conferences but provides no new financial results, guidance, or other material company catalyst. The search result also includes an earnings-date announcement, which is not treated as a separate news item.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments